Could a bladder pill save your sight? new trial tests mirabegron for dry AMD
NCT ID NCT07305298
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests whether mirabegron, a drug used for overactive bladder, can help people with dry age-related macular degeneration (AMD). Researchers will give 312 patients aged 50-80 either mirabegron or a standard bladder drug for 12 months and check for changes in the retina. The goal is to see if mirabegron can slow or improve the eye condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERACTIVE BLADDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federico II
Naples, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirabegron (50 mg daily)
What this could lead to
If it works, this could point toward a new treatment for dry AMD using an existing drug.
What could go wrong
This is a small, early-stage trial with no random assignment, so results may not be conclusive. The drug is not designed for eye disease and may not improve vision.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.